KRAS and infection: Since the development of DAAs, this infection is curable by a pharmacologic treatment consisting of 8–16 weeks of therapeutic combinations of an inhibitor of protease NS3/4A, an inhibitor of the non-structural protein NS5A, or an inhibitor of the polymerase NS5B [31].